Uterine Cancer Screening

In recent years, genetic testing for hereditary uterine cancer has become more common.

Recent research highlights the role of proteins, encoded by the genes BRCA1, BRCA2, MLH1 and MLH2, in protecting the normal cells in the uterus from becoming cancerous. However, when genetic mutations occur, the cells in the uterus fail to function properly and succumb to the development of uterine cancer. Genetic mutations, therefore, significantly increase a woman’s risk for endometrial cancer.

Screening for Genetic Mutations Associated with Endometrial Cancer

Studies have shown that women with inherited genetic mutations are at significantly greater risk of breast, ovarian, and endometrial cancer. Research has also shown that women who do not undergo genetic testing for the presence of genetic mutations are likely to develop one or more malignancies, such as that of the uterus, before the age of fifty. Increased risk of developing uterine cancer in women with these genetic mutations is estimated at around sixty percent by the age of seventy.

Genetic Testing for Uterine Cancer

Genetic testing for the specific genetic mutations that are known to increase the risk of uterine cancer is vital, not only as a preventive measure against endometrial cancer, but also to ensure early detection of existing uterine cancer. Genetic testing for uterine cancer should start as early as age 35 for women with known hereditary genetic predisposition towards uterus problems.

Genetic Testing for Other Malignancies

The same genetic mutations that place women at greater risk of uterine cancer are also linked with an increased risk for developing malignancies of the following organs in women:

Genetic testing is also important for prostate cancer in men and colon cancer in both men and women.